Development of the Oncology Opportunity Cost Assessment Tool

Malignant Solid Neoplasm Clinical Trial

Official title:

Development of the Oncology Opportunity Cost Assessment Tool (OOCAT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04694911
• Other study ID #: 19G.854
• Status: Completed
• Start date: November 21, 2019
• Est. completion date: July 31, 2021

Study information

• Verified date: August 2022
• Source: Thomas Jefferson University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study develops and tests an instrument to measure opportunity costs called the Oncology Opportunity Cost Assessment Tool (OOCAT) in cancer patients. Patients experience significant costs, both direct financial as well as indirect costs, associated with seeking cancer treatment. While the direct financial impact of care on patients is receiving increased attention, other important consequences, such as opportunity cost, remain largely unmeasured. Opportunity cost is an economics term that refers to the loss of potential benefits from other options when one option is chosen - if resources are used for one purpose, they are no longer available for the next best option. The information and knowledge gained from this study may help researchers develop the OOCAT, which may allow them to understand the opportunity cost of treatment for each patient. The OOCAT may then be used to determine not just the best medications for patients, but also the best comprehensive treatment plan that will allow them to get the right treatment in the right place at the right time.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: July 31, 2021
• Est. primary completion date: May 11, 2021
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Treated for cancer at one of the 3 participating sites (Jefferson Center City, Jefferson Methodist Hospital, Jefferson Abington)

• English speaking

• Able to attend and participate in a focus group

Exclusion Criteria:

• Treated at a Jefferson site other than the ones mentioned

• Non-English Speaking

Related Conditions & MeSH terms

• Hematopoietic and Lymphoid Cell Neoplasm
• Malignant Solid Neoplasm
• Neoplasms

Intervention

Behavioral:
• Focus Group
Participate in focus group

Other:
• Interview
Complete cognitive interview
• Research or Clinical Assessment Tool
Receive OOCAT

Locations

Country	Name	City	State
United States	Sidney Kimmel Cancer Center at Thomas Jefferson University	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient-level opportunity costs associated with oncology care	Patient-identified themes that contribute to opportunity cost will be generated via patient focus groups	1 Day of Interview
Primary	Development of the Oncology Opportunity Cost Assessment Tool (OOCAT)	Will organize themes into domains and will generate items representing each of the themes for inclusion in an instrument designed to measure patient opportunity cost of seeking care. Will perform cognitive interviews with a random sampling of patients from the cancer center to test initial instrument items to ensure content validity and clarity of each item.	1 Day of Interview
Primary	Implementation of OOCAT	Will test the instrument as developed with patients receiving oncology care across the Jefferson Health System to gather preliminary data informing the reliability of the scale to measure opportunity cost of seeking care.	1 Day of OOCAT administration